## Wednesday, September 14

6:00 p.m.-7:00 p.m.

**Keynote Lecture** 

**Grand Ballroom** 

Opening remarks

Conference Chairperson: Elizabeth H. Blackburn,

University of California, San Francisco, CA

Building molecules to guide anticancer therapy\* **Roger Y. Tsien**, University of California, San Diego,

La Jolla, CA

7:00 p.m.-8:30 p.m.

**Opening Welcome Reception** 

InterContinental Ballroom

### **Thursday, September 15**

7:00 a.m.-8:00 a.m.

**Continental Breakfast** 

Pacific Terrace

### **Meet-the-Expert Roundtables**<sup>†</sup>

Jackson, Howard, and Fremont

<sup>†</sup>Advance sign up is required at Registration in the Grand Ballroom Foyer.

8:00 a.m.-10:00 a.m.

**Session 1: Understanding the Cancer Genome** 

**Grand Ballroom** 

**Chairperson: David P. Lane,** Agency for Science, Technology, and Research (A\*STAR), Singapore

### **Special Opening Lecture:**

Cancer genomes and their implications for basic and applied research\*

**Bert Vogelstein,** Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Discovery in cancer genomics by next-generation sequencing and data analysis\*

**Elaine Mardis,** Washington University School of Medicine, St. Louis, MO

Insights into tumor biology and therapeutic resistance from systematic genetic studies

Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA

10:00 a.m.-10:30 a.m.

**Break** 

10:30 a.m.-12:30 p.m.

**Session 2: Cancer as an Organ** 

Grand Ballroom

Chairperson: Zena Werb, University of California,

San Francisco, CA

Normalizing the tumor microenvironment to enhance therapeutic outcome\*

Rakesh K. Jain, Massachusetts General Hospital, Boston, MA

The role of nitric oxide in tumor microenvironment\*

Dai Fukumura, Massachusetts General Hospital, Boston, MA

DNA-damaging anticancer therapies modify the tumor microenvironment\*

Judith Campisi, Buck Institute for Age Research, Novato, CA

Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis\*\*

**Myriam Labelle,** Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA

<sup>\*</sup>An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

<sup>\*\*</sup>Short talks from proffered papers.

A genetic screen for novel determinants of anoikis resistance identifies PVRI 4\*\*

Natalya N. Pavlova, Harvard Medical School, Boston, MA

12:30 p.m.-2:00 p.m.

Lunch on own

## **Mentoring Roundtables**<sup>†</sup>

Jackson, Howard, and Fremont

<sup>†</sup>Advance sign up is required at Registration in the Grand Ballroom Foyer.

### 2:00 p.m.-4:00 p.m.

### **Session 3: Immunomodulation**

Grand Ballroom

**Chairperson: Dai Fukumura,** Massachusetts General Hospital, Boston, MA

Immune checkpoint blockade in cancer therapy:

New insights and opportunities

**James P. Allison,** Memorial Sloan-Kettering Cancer Center, New York, NY

Blockade of immunologic checkpoints in cancer therapy: The B7-H1/PD-1 pathway\*

Suzanne L. Topalian, Johns Hopkins University, Baltimore, MD

Natural killer cells in host defense against cancer\*

Lewis L. Lanier, University of California, San Francisco, CA

## 4:30 p.m.-7:30 p.m.

### **Poster Session A and Reception**

InterContinental Ballroom

See detailed listing for Poster Session A beginning on page 17.

## Friday, September 16

7:00 a.m.-8:00 a.m. Continental Breakfast

Pacific Terrace

### **Meet-the-Expert Roundtables**<sup>†</sup>

Jackson, Howard, and Fremont

<sup>†</sup>Advance sign up is required at Registration in the Grand Ballroom Foyer.

### 8:00 a.m.-10:00 a.m.

# Session 4: Genomic Instability and Genome Surveillance Grand Ballroom

**Chairperson: Elizabeth H. Blackburn,** University of California, San Francisco, CA

How the p53 pathway controls the response to chemotherapy\* **David P. Lane,** Agency for Science, Technology, and Research (A\*STAR), Singapore

Exploiting cell cycle checkpoint control in cancer therapy **Helen M. Piwnica-Worms,** Washington University School of Medicine, St. Louis, MO

Targeting the Fanconi anemia/BRCA pathway in cancer therapy\* **Alan D. D'Andrea,** Dana-Farber Cancer Institute, Boston, MA

The BLM helicase facilitates RNA polymerase I-mediated ribosomal RNA transcription\*\*

**Patrick Grierson,** The Ohio State University College of Medicine, Columbus, OH

Regulation of the Fanconi anemia pathway by a SUMO-like delivery network\*\*

**Kailin Yang,** Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

<sup>\*</sup>An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

<sup>\*\*</sup>Short talks from proffered papers.

10:00 a.m.-10:30 a.m. Break

10:30 a.m.-12:30 p.m. Session 5: Risk Factors

Grand Ballroom

**Chairperson: Helen M. Piwnica-Worms,** Washington University School of Medicine, St. Louis, MO

New insights into the microenvironment and metastasis\* **Zena Werb,** University of California, San Francisco, CA

Systems genetics analysis of cancer susceptibility **Allan Balmain,** UCSF Helen Diller Family Comprehensive
Cancer Center, San Francisco, CA

Ribosomal protein-Mdm2-p53 signaling and metabolism **Yanping Zhang,** University of North Carolina, Chapel Hill, NC

Human Merkel cell polyomavirus causes Merkel cell carcinoma: Implication of viral etiology in human cancers\*\* **Huichen Feng,** University of Pittsburgh Cancer Institute,

Pittsburgh, PA

Why redheads are at increased risk of melanoma: A novel BRAF mutant mouse model\*\*

**Devarati Mitra,** Harvard Medical School, Massachusetts General Hospital, Boston, MA 12:30 p.m.-2:00 p.m.

Lunch on own

**Mentoring Roundtables**<sup>†</sup>

Jackson, Howard, and Fremont

<sup>†</sup>Advance sign up is required at Registration in the Grand Ballroom Foyer.

2:00 p.m.-4:00 p.m.

Session 6: Reprogramming and Plasticity of Cancer Stem Cells

**Grand Ballroom** 

**Chairperson: Judith Campisi**, Buck Institute for Age Research, Novato, CA

Induction of pluripotency by defined factors\* **Shinya Yamanaka,** Kyoto University, Kyoto, Japan

Stem cell self-renewal and cancer cell proliferation **Sean J. Morrison,** University of Michigan, Ann Arbor, MI

Reprogramming cell fate by mimicking natural mechanisms\* **Helen M. Blau,** Stanford University School of Medicine, Stanford, CA

The complexity of tumor cell hierarchies\*

Jeremy N. Rich, The Cleveland Clinic, Cleveland, OH

4:30 p.m.-7:30 p.m.

**Poster Session B and Reception** 

InterContinental Ballroom

See detailed listing for Poster Session B beginning on page 21.

<sup>\*</sup>An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

<sup>\*\*</sup>Short talks from proffered papers.

## Saturday, September 17

7:00 a.m.-8:00 a.m. Continental Breakfast

Pacific Terrace

### **Meet-the-Expert Roundtables**<sup>†</sup>

Jackson, Howard, and Fremont

<sup>†</sup>Advance sign up is required at Registration in the Grand Ballroom Foyer.

#### 8:00 a.m.-10:00 a.m.

# **Session 7: Emerging Technologies for Cancer Research**Grand Ballroom

**Chairperson: Scott Manalis,** Massachusetts Institute of Technology, Cambridge, MA

Measuring evolution in neoplasms\*

Carlo Maley, University of California, San Francisco, CA

Technologies for detecting and analyzing proteins in living cells\* **Alice Y. Ting,** Massachusetts Institute of Technology,

Cambridge, MA

Microfluidic measurements of single cell mass reveal how growth and division are coordinated\*

**Scott Manalis** 

An oncolytic vaccinia virus encoding the human sodium iodide symporter facilitates long-term deep tissue image monitoring of virotherapy and targeted radiotherapy of pancreatic cancer\*\* **Dana Haddad,** Memorial Sloan-Kettering Cancer Center, New York, NY

From prediction to prognosis and therapeutics: The power of breast cancer transcriptional networks\*\*

Bin Zhang, Sage Bionetworks, Seattle, WA

10:00 a.m.-10:30 a.m. Break

10:30 a.m.-12:30 p.m.

**Session 8: Metabolism and Autophagy** 

Grand Ballroom

**Chairperson: William G. Kaelin, Jr.,** Dana-Farber Cancer Institute, Boston, MA

Role of autophagy and cellular metabolism in cancer **Eileen P. White,** UMDNJ-The Cancer Institute of New Jersey, New Brunswick, NJ

Oncogene regulation of the autophagy machinery\* **Beth C. Levine,** University of Texas Southwestern Medical Center, Dallas, TX

2-Oxoglutarate-dependent dioxygenases: Potential links between altered metabolism and cancer William G. Kaelin, Jr.

PICT1/GLTSCR2 is a critical nucleolar binding partner of RPL11 that regulates the MDM2-p53 pathway and tumor growth\*\* **Kohichi Kawahara,** Kyushu University, Fukuoka, Japan

A mechanistic investigation into the dynamic alliance between autophagy and tumor suppression in prostate cancer\*\* **Lorena A. Puto,** Salk Institute, La Jolla, CA

12:30 p.m.-2:00 p.m. Lunch on own

### **Mentoring Roundtables**<sup>†</sup>

Jackson, Howard, and Fremont

<sup>†</sup>Advance sign up is required at Registration in the Grand Ballroom Foyer.

<sup>\*</sup>An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

<sup>\*\*</sup>Short talks from proffered papers.

2:00 p.m.-4:00 p.m.

**Session 9: Epigenetics and Cancer** 

**Grand Ballroom** 

**Chairperson: Helen M. Blau,** Stanford University School of Medicine. Stanford. CA

DNA methylation and nucleosome repositioning in cancer\* **Peter A. Jones,** USC Norris Comprehensive Cancer Center, Los Angeles, CA

Role of Tet1-catalyzed 5mC hydroxylation in transcriptional regulation and ES cell maintenance\*

**Yi Zhang,** Howard Hughes Medical Institute at University of North Carolina, Chapel Hill, NC

Targeting epigenetic reader proteins in cancer therapy **James E. Bradner,** Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Egfr is essential for Ras-driven pancreatic cancer development\*\*

**Barbara M. Grüner,** Klinikum Rechts der Isar, Technical University Munich, Munich, Germany

Extracellular miR-92a secreted by human leukemia cells enhances endothelial cell migration in HUVECs\*\*

Tomohiro Umezu, Tokyo Medical University, Tokyo, Japan

4:30 p.m.-7:30 p.m.

**Poster Session C and Reception** 

InterContinental Ballroom

See detailed listing for Poster Session C beginning on page 25.

### Sunday, September 18

7:00 a.m.-8:00 a.m.

**Continental Breakfast** 

Pacific Terrace

### **Meet-the-Expert Roundtables**<sup>†</sup>

Jackson, Howard, and Fremont

<sup>†</sup>Advance sign up is required at Registration in the Grand Ballroom Foyer.

8:00 a.m.-10:00 a.m.

**Session 10: Killing the Tumor Cell** 

**Grand Ballroom** 

**Chairperson: René Bernards,** The Netherlands Cancer Institute, Amsterdam, The Netherlands

Harnessing genetic dependencies in cancer therapy\* **Alan Ashworth,** Institute of Cancer Research, London,
United Kingdom

The application of synthetic lethality as a therapeutic approach to cancer\*

**Christopher Lord,** Institute of Cancer Research, London, United Kingdom

Drugging the undruggable: Small molecule inhibition of the Ras oncoprotein\*

Guowei Fang, Genentech, Inc., San Francisco, CA

The canonical Wnt pathway participates in anchorageindependent growth in a subset of heterogeneous tumor cells derived from a single murine pancreatic tumor\*\* **Man Yeung Heung,** University of Edinburgh CRUK Centre,

Edinburgh, United Kingdom

Germline submicroscopic chromosome imbalances in pediatric cancer\*\*

Carla Rosenberg, University of São Paulo, São Paulo, Brazil

<sup>\*</sup>An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

<sup>\*\*</sup>Short talks from proffered papers.

10:00 a.m.-10:15 a.m.

**Break** 

10:15 a.m.-12:15 p.m.

**Session 11: Mechanisms of Drug Resistance** 

**Grand Ballroom** 

**Chairperson: Elizabeth Blackburn,** University of California, San Francisco, CA

Using old mouse models to identify new cancer drug targets\* **Michael T. Hemann,** Massachusetts Institute of Technology,
Cambridge, MA

Finding mechanisms of cancer drug resistance through functional genetic screens\*

**René Bernards,** The Netherlands Cancer Institute, Amsterdam, The Netherlands Overcoming intrinsic and acquired resistance to targeted therapies

**Jeffrey A. Engelman,** Massachusetts General Hospital, Boston, MA

Inhibition of RNA polymerase I as a therapeutic strategy for cancer-specific activation of p53\*\*

**Megan J. Bywater,** Peter MacCallum Cancer Centre, Melbourne, Australia

Important bidirectional function in the Notch-Delta signaling in pancreatic carcinogenesis and metastasis\*\*

Pawel K. Mazur, Stanford University, Stanford, CA

12:15 p.m. **Departure** 

<sup>\*</sup>An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

<sup>\*\*</sup>Short talks from proffered papers.